IJO International Journal of Oncology 1019-6439 1791-2423 D.A. Spandidos 10.3892/ijo.2015.3265 ijo-48-02-0854 Corrigendum Corrigendum 2 2016 25 11 2015 48 2 854 854 Copyright: © Fujiwara et al. 2016 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells

JUN FUJIWARA, YOSHIHIRO SOWA, MANO HORINAKA, MAKOTO KOYAMA, MIKI WAKADA, TSUNEHARU MIKI and TOSHIYUKI SAKAI

Int J Oncol 40: 1483–1491, 2012; DOI: 10.3892/ijo.2012.1353

After the publication of the article, the authors noted that in Fig. 5c, the image of β-actin is incorrect. The corrected version of Fig. 5c is shown below. In Fig. 6a, the histogarms are incorrect, and the corrected Fig. 6a is shown below. In Fig. 7, the figure of PrEC is incorrect, and the corrected Fig. 7 (PrEC) is shown below. The corrected figures demonstrate the same findings as the original figures. These corrections do not alter the interpretation of the results and conclusions.